Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$130B
| $2.56B | 2.21% |
43,497,131
-22,494,980
| -34% | -$1.35B |
|
|
NVO
2
Novo Nordisk
NVO
$207B
| $1.88B | 1.62% |
57,419,662
+1,699,210
| +3% | +$54.2M |
|
|
3
AbbVie
ABBV
$442B
| $1.87B | 1.61% |
19,021,869
+5,466,020
| +40% | +$481M |
|
|
4
Zoom
ZM
$31.1B
| $1.84B | 1.59% |
7,256,035
+4,478,495
| +161% | +$806M |
|
5
Chipotle Mexican Grill
CMG
$40.5B
| $1.7B | 1.47% |
80,717,100
-11,245,000
| -12% | -$208M |
|
6
Vertex Pharmaceuticals
VRTX
$134B
| $1.68B | 1.45% |
5,781,332
-1,078,350
| -16% | -$292M |
|
7
VeriSign
VRSN
$26B
| $1.51B | 1.31% |
7,310,690
-794,600
| -10% | -$165M |
|
8
Atlassian
TEAM
$39.1B
| $1.23B | 1.06% |
6,835,013
+400,989
| +6% | +$66.6M |
|
9
Tesla
TSLA
$1.31T
| $1.2B | 1.03% |
16,603,590
+5,091,000
| +44% | +$275M |
|
|
10
Baidu
BIDU
$35.9B
| $1.16B | 1% |
9,663,857
+3,953,814
| +69% | +$423M |
|
11
Palo Alto Networks
PANW
$313B
| $1.15B | 0.99% |
29,941,512
-2,574,594
| -8% | -$90.7M |
|
12
Biogen
BIIB
$30.1B
| $1.05B | 0.9% |
3,905,922
-567,990
| -13% | -$171M |
|
13
Pinduoduo
PDD
$129B
| $957M | 0.83% |
11,150,680
+3,279,206
| +42% | +$197M |
|
14
Target
TGT
$69.2B
| $945M | 0.82% |
7,880,897
+871,738
| +12% | +$99.5M |
|
15
Walmart Inc
WMT
$901B
| $929M | 0.8% |
23,272,842
-6,133,800
| -21% | -$252M |
|
|
16
Humana
HUM
$44.8B
| $902M | 0.78% |
2,327,242
-1,201,900
| -34% | -$450M |
|
17
Monster Beverage
MNST
$89.2B
| $895M | 0.77% |
51,630,360
-2,796,008
| -5% | -$45.6M |
|
|
18
Kroger
KR
$34.5B
| $887M | 0.77% |
26,212,088
+13,242,785
| +102% | +$430M |
|
19
GSK
GSK
$102B
| $838M | 0.72% |
16,441,003
-2,020,160
| -11% | -$104M |
|
20
Fortinet
FTNT
$119B
| $820M | 0.71% |
29,868,435
-453,505
| -1% | -$11.4M |
|
21
Newmont
NEM
$124B
| $794M | 0.69% |
12,856,785
+903,598
| +8% | +$53.5M |
|
22
Franco-Nevada
FNV
$46.4B
| $792M | 0.68% |
5,672,083
+767,265
| +16% | +$102M |
|
23
Novartis
NVS
$294B
| $724M | 0.63% |
8,294,608
-196,800
| -2% | -$17M |
|
|
B
24
Barrick Mining
B
$67.2B
| $722M | 0.62% |
26,806,209
+1,673,938
| +7% | +$41.8M |
|
25
eBay
EBAY
$47.2B
| $697M | 0.6% |
13,279,334
+789,463
| +6% | +$33.4M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.